165 related articles for article (PubMed ID: 20150762)
1. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.
Kaplan-Lefko PJ; Graves JD; Zoog SJ; Pan Y; Wall J; Branstetter DG; Moriguchi J; Coxon A; Huard JN; Xu R; Peach ML; Juan G; Kaufman S; Chen Q; Bianchi A; Kordich JJ; Ma M; Foltz IN; Gliniak BC
Cancer Biol Ther; 2010 Apr; 9(8):618-31. PubMed ID: 20150762
[TBL] [Abstract][Full Text] [Related]
2. Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5.
Rossin R; Kohno T; Hagooly A; Sharp T; Gliniak B; Arroll T; Chen Q; Hewig A; Kaplan-Lefko P; Friberg G; Radinsky R; Evelhoch JL; Welch MJ; Hwang DR
J Nucl Med; 2011 Jun; 52(6):942-9. PubMed ID: 21571804
[TBL] [Abstract][Full Text] [Related]
3. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
4. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling.
Zoog SJ; Ma CY; Kaplan-Lefko PJ; Hawkins JM; Moriguchi J; Zhou L; Pan Y; Hsu CP; Friberg G; Herbst R; Hill J; Juan G
Cytometry A; 2010 Sep; 77(9):849-60. PubMed ID: 20623688
[TBL] [Abstract][Full Text] [Related]
5. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.
Kang Z; Goldstein SD; Yu Y; Meltzer PS; Loeb DM; Cao L
Br J Cancer; 2015 Sep; 113(6):894-901. PubMed ID: 26291055
[TBL] [Abstract][Full Text] [Related]
6. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.
Rosevear HM; Lightfoot AJ; Griffith TS
Curr Opin Investig Drugs; 2010 Jun; 11(6):688-98. PubMed ID: 20496264
[TBL] [Abstract][Full Text] [Related]
7. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Fuchs CS; Fakih M; Schwartzberg L; Cohn AL; Yee L; Dreisbach L; Kozloff MF; Hei YJ; Galimi F; Pan Y; Haddad V; Hsu CP; Sabin A; Saltz L
Cancer; 2013 Dec; 119(24):4290-8. PubMed ID: 24122767
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
9. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
10. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
11. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
Zeng Y; Wu XX; Fiscella M; Shimada O; Humphreys R; Albert V; Kakehi Y
Int J Oncol; 2006 Feb; 28(2):421-30. PubMed ID: 16391797
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
[TBL] [Abstract][Full Text] [Related]
15. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
[TBL] [Abstract][Full Text] [Related]
16. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
[TBL] [Abstract][Full Text] [Related]
17. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
[TBL] [Abstract][Full Text] [Related]
19. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
Sasaki H; Ohara N; Xu Q; Wang J; DeManno DA; Chwalisz K; Yoshida S; Maruo T
J Clin Endocrinol Metab; 2007 Feb; 92(2):616-23. PubMed ID: 17105846
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
